Last reviewed · How we verify
Dolutegravir placebo twice daily
This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to assess the efficacy of dolutegravir.
This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to assess the efficacy of dolutegravir. Used for HIV-1 infection (Phase 3 trial comparator arm).
At a glance
| Generic name | Dolutegravir placebo twice daily |
|---|---|
| Also known as | GSK1349572 Placebo |
| Sponsor | ViiV Healthcare |
| Drug class | Placebo (integrase strand transfer inhibitor comparator) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Dolutegravir (the active comparator) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing viral DNA from integrating into the host genome. The placebo arm in this Phase 3 trial allows researchers to measure the true clinical benefit of dolutegravir treatment versus no active intervention.
Approved indications
- HIV-1 infection (Phase 3 trial comparator arm)
Common side effects
Key clinical trials
- A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (PHASE3)
- A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (PHASE3)
- Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir (PHASE3)
- Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dolutegravir placebo twice daily CI brief — competitive landscape report
- Dolutegravir placebo twice daily updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI